Nimbus declares positive data from Phase I/II solid tumour therapy trial

Nimbus Therapeutics has released encouraging results from its Phase I/II clinical trial of NDI-101150, an oral small-molecule inhibitor targeting hematopoietic progenitor kinase 1 (HPK1), in adults with advanced solid tumors. The open-label trial is evaluating NDI-101150 as a standalone therapy (50mg to 200mg doses) and in combination with pembrolizumab.

As of March 18, data from 44 subjects in dose escalation and 15 in dose expansion cohorts were analyzed. Notably, 16.7% of patients saw clinical benefits from NDI-101150 monotherapy, including one with renal cell carcinoma achieving complete response and another with partial response, despite prior treatments. Three patients with RCC, pancreatic cancer, and endometrial cancer respectively, had stable disease for over six months, with one RCC patient's lasting 21 months. Six out of eight RCC patients demonstrated stable disease or better. NDI-101150 exhibited favorable tolerability, with an acceptable safety profile. These findings were presented at the ASCO Annual Meeting, indicating NDI-101150's potential in inhibiting tumor growth significantly.